Glizid-XR 60 Tablet contains Gliclazide 60 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. Gliclazide exerts its antihyperglycemic effect primarily by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control. It is particularly useful in patients whose diabetes cannot be adequately controlled by diet and exercise alone. Glizid-XR 60 is formulated as an extended-release tablet, allowing for once-daily dosing and providing a sustained reduction in blood glucose levels throughout the day. This formulation enhances patient compliance and minimizes the risk of hypoglycemia compared to immediate-release preparations. The medication should be used as part of a comprehensive diabetes management plan, including diet modification, exercise, and regular blood glucose monitoring. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to sulfonylureas. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy with Glizid-XR 60 Tablet.